Inez H G B Ramakers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4668263/publications.pdf

Version: 2024-02-01

65 2,718 papers citations

304602 197736 49
h-index g-index

70 70 all docs citations

70 times ranked 4540 citing authors

#	Article	IF	Citations
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
2	A Scoping Review of Communicating Neuropsychological Test Results to Patients and Family Members. Neuropsychology Review, 2022, 32, 294-315.	2.5	12
3	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
4	Screening for neuropsychological assessment in the diagnostics of Neurocognitive disorder. International Psychogeriatrics, 2022, , 1-7.	0.6	0
5	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	1.2	6
6	A comparison of two approaches for modeling dementia progression in a changing patient context. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	3
7	Feasibility Study of an Internet-Based Platform for Tele-Neuropsychological Assessment of Elderly in Remote Areas. Diagnostics, 2022, 12, 925.	1.3	6
8	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
9	Neuropsychological assessment and diagnostic disclosure at a memory clinic: A qualitative study of the experiences of patients and their family members. Clinical Neuropsychologist, 2021, 35, 1398-1414.	1.5	19
10	Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Molecular Psychiatry, 2021, 26, 897-906.	4.1	58
11	Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study. Quality of Life Research, 2021, 30, 867-879.	1.5	4
12	Alzheimer's disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment <scp>,</scp> and Alzheimer's disease dementia. International Journal of Geriatric Psychiatry, 2021, 36, 224-234.	1.3	20
13	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102712.	1.4	42
14	An Exploratory Study of the Development and Pilot Testing of an Interactive Visual Tool of Neuropsychological Test Results in Memory Clinics. Journal of Alzheimer's Disease, 2021, 79, 1157-1170.	1.2	3
15	Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. Diabetologia, 2021, 64, 2445-2457.	2.9	13
16	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	2.4	6
17	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 107, 1-10.	1.5	12
18	Remote cognitive assessment of older adults in rural areas by telemedicine and automatic speech and video analysis: protocol for a cross-over feasibility study. BMJ Open, 2021, 11, e047083.	0.8	0

#	Article	IF	CITATIONS
19	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Scientific Reports, 2021, 11, 22675.	1.6	27
20	Remote cognitive assessment of older adults in rural areas by telemedicine and automatic speech and video analysis: protocol for a cross-over feasibility study. BMJ Open, 2021, 11, e047083.	0.8	5
21	The prevalence of vascular risk factors in different AD biomarker profiles. Alzheimer's and Dementia, 2021, 17, .	0.4	O
22	Automated speech analysis for detection of cognitive and emotional changes. Alzheimer's and Dementia, 2021, 17 , .	0.4	0
23	Interstitial fluid as a proxy of glymphatic dysfunction in patients with cognitive impairment: The necessity of threeâ€directional intravoxel incoherent motion. Alzheimer's and Dementia, 2021, 17, .	0.4	0
24	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 256-264.	1.2	6
25	CSF Aβ42, Pâ€ŧau and noradrenaline metabolite MHPG levels are synergistically related to cortical thickness in a memory clinic population. Alzheimer's and Dementia, 2020, 16, e037481.	0.4	0
26	Vascular and neurodegenerative imaging markers are associated with increased interstitial fluid diffusion in memory clinic patients. Alzheimer's and Dementia, 2020, 16, e039700.	0.4	0
27	Correlations of plasma kynurenines with CSF levels, and their relation to markers of Alzheimer's disease pathology, diagnostic phases and cognitive performance. Alzheimer's and Dementia, 2020, 16, e041474.	0.4	0
28	CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.4	1
29	Validation of a telemedicine tool for patient monitoring in clinical dementia trials. Alzheimer's and Dementia, 2020, 16, e047345.	0.4	0
30	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. American Journal of Geriatric Psychiatry, 2020, 28, 735-744.	0.6	33
31	Cognitive and functional progression of dementia in two longitudinal studies. International Journal of Geriatric Psychiatry, 2019, 34, 1623-1632.	1.3	6
32	Association Between Proxy- or Self-Reported Cognitive Decline and Cognitive Performance in Memory Clinic Visitors. Journal of Alzheimer's Disease, 2019, 70, 1225-1239.	1.2	17
33	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. Neuroscience and Biobehavioral Reviews, 2019, 107, 346-359.	2.9	29
34	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 389-397.	1.2	30
35	A survey on the prevalence of apathy in elderly people referred to specialized memory centers. International Journal of Geriatric Psychiatry, 2019, 34, 1369-1377.	1.3	16
36	Development of memory clinics in the Netherlands over the last 20 years. International Journal of Geriatric Psychiatry, 2019, 34, 1267-1274.	1.3	30

#	Article	IF	CITATIONS
37	Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer's disease dementia: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2019, 96, 302-315.	2.9	23
38	The clinical course and interrelations of dementia related symptoms. International Psychogeriatrics, 2018, 30, 859-866.	0.6	22
39	Association of Cerebral Amyloid- \hat{l}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
40	P2â€⊋70: INCREASED CSF AMYLOIDâ€Î² 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGI IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	NITIVE 0.4	0
41	P3â€232: THE ASSOCIATION BETWEEN BLOODâ€BRAINâ€BARRIER DYSFUNCTION AND CSF Pâ€TAU IS MEDIATED BETAâ€AMYLOID IN THE PRESENCE OF ELEVATED ILâ€6. Alzheimer's and Dementia, 2018, 14, P1160.) BY 0.4	0
42	P1â€332: APOLIPOPROTEIN E GENOTYPE AND AFFECTIVE NEUROPSYCHIATRIC SYMPTOMS: A SYSTEMATIC REVIEW AND METAâ€ANALYSIS. Alzheimer's and Dementia, 2018, 14, P420.	0.4	0
43	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2017, 72, 846-854.	1.7	69
44	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
45	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	1.2	27
46	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	3.0	43
47	Anxiety as a Predictor for Cognitive Decline and Dementia: A Systematic Review and Meta-Analysis. American Journal of Geriatric Psychiatry, 2016, 24, 823-842.	0.6	239
48	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurology, 2016, 16, 242.	0.8	17
49	P1-366: Subjective Versus Objective Cognitive Decline in Memory Clinic Visitors., 2016, 12, P571-P571.		0
50	The Diagnostic and Prognostic Value ofÂNeuropsychological Assessment inÂMemory Clinic Patients. Journal of Alzheimer's Disease, 2016, 55, 679-689.	1.2	20
51	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
52	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF)., 2015, 11, P130-P130.		0
53	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test., 2015, 11, P272-P272.		O
54	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study., 2015, 11, P297-P297.		1

#	Article	IF	CITATIONS
55	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment., 2015, 11, P177-P177.		0
56	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors., 2015, 11, P260-P261.		0
57	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	1.0	23
58	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
59	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	1.1	72
60	The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results. BMC Neurology, 2014, 14, 254.	0.8	57
61	P1-182: THE EFFECT OF PSYCHOLOGICAL DISTRESS AND PERSONALITY TRAITS ON COGNITIVE TEST PERFORMANCES AND THE RISK OF DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. , 2014, 10, P366-P366.		O
62	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 501-509.	1.2	34
63	Development of memory clinics in the Netherlands: 1998 to 2009. Aging and Mental Health, 2011, 15, 34-39.	1.5	29
64	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2010, 25, 71-77.	0.3	10
65	Characteristics of helpâ€seeking behaviour in subjects with subjective memory complaints at a memory clinic: a caseâ€control study. International Journal of Geriatric Psychiatry, 2009, 24, 190-196.	1.3	63